Once-weekly insulin offers hope for better diabetes treatment

22 September 2022
novo_nordisk_2021_flags_large

More data from Novo Nordisk’s (NOV: N) ONWARDS program show positive results for the firm’s new once-weekly insulin product, insulin icodec.

While Novo has placed significant strategic emphasis on the development of its GLP-1 franchise, including a potentially highly lucrative expansion into diabetes, the company’s core insulin business remains essential to its financial future.

Analysts have forecast that the insulin market in America could soon be worth over $10 billion, with around a tenth of that going to new copycats.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical